Trial production of some products of the Hailier (603639.SH) subsidiary Qingdao Hengning Biology Phase II Project

Zhitongcaijing · 1d ago

Zhitong Finance App News, Hailier (603639.SH) announced that the company's wholly-owned subsidiary, Qingdao Hengning Biotechnology Co., Ltd. (“Qingdao Hengning Biology”), has completed the construction and equipment installation and commissioning of the project with an annual output of 6,000 tons of fluorazolamide and an annual output of 3,000 tons of biphenylpyrimidine. Recently, after the trial production plan has been reviewed and approved by experts and filed by relevant authorities, it will officially enter the trial production stage.

The construction and commissioning of these original drugs and intermediates is in line with the company's strategic plan, helping to further enrich the company's range of original drug products. The integrated advantages of original drug formulations are more prominent, and further enhance core competitiveness and sustainable development capabilities. If the project is fully put into operation, it will help the company reduce production costs of the company's products, increase new profit growth points, and enhance the overall competitiveness and profitability of the company's market on the basis of stable development of the main business.